You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DPP-4 Inhibitors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ive Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Active, not recruiting
  • Diabetes
  • Boston, Massachusetts
    Brigham and Women's Hospital
Mar 3, 2023

Diabete Type 2 Trial in El Sadat (Sitagliptin 50 mg, Empagliflozin 12.5 MG, Sitagliptin 50 mg + Empagliflozin 12.5 MG)

Completed
  • Diabete Type 2
  • Sitagliptin 50 mg
  • +3 more
  • El Sadat, Egypt
    University of Sadat City
Apr 27, 2022

Therapeutic Drug Use for CKD Patients

Active, not recruiting
  • Chronic Kidney Disease
  • angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
  • Jinan, Shandong, China
    Xiao Li，MD
Apr 18, 2023

Type 2 Diabetes to Assess Risk of Liver Injury, Kidney Injury,

Completed
  • Diabetes Mellitus, Type 2
  • One Or Multiple Sites, United Kingdom
    RTI health solutions
Aug 2, 2022

Based on Data From German Sick Funds That Looks at Costs of

Completed
  • Diabetes Mellitus, Type 2
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
Jan 18, 2022

Diabetes, Stroke Trial in Chiayi City (Metformin plus Pioglitazone plus an SGLT2 inhibitor)

Recruiting
  • Diabetes Mellitus
  • Stroke
  • Metformin plus Pioglitazone plus an SGLT2 inhibitor
  • Chiayi City, Taiwan
    Chang Gung Memorial Hospital, Chiayi Branch
Jan 11, 2022

Time in Range Trial in Cairo (Dipeptidyl peptidase-4 inhibitors)

Completed
  • Time in Range
  • Dipeptidyl peptidase-4 inhibitors
  • Cairo, Egypt
    Nancy Elbarbary
Aug 26, 2023

Metformin and DPP4 Inhibitors on Cognition and Cardiovascular

Recruiting
  • Type 2 Diabetes Mellitus
  • Cairo, Al Kasr Al Aini, Egypt
    National Institute of diabetes and endocrinology
Jun 19, 2022

Empa PASS on Urinary Tract Malignancies

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Helsinki, Finland
  • +2 more
Aug 8, 2022

Type II Diabetes in Subjects BMI 27 to 32 Trial in Singapore (Roux-en-Y Gastric Bypass (RYGB), Incretin analogues, Xenical)

Completed
  • Type II Diabetes in Subjects BMI 27 to 32
  • Roux-en-Y Gastric Bypass (RYGB)
  • +4 more
  • Singapore, Singapore
    Khoo Teck Puat Hospital
Jun 22, 2022

Abdominal Obesity, Type 2 Diabetes Trial in San Luis Potosi (Biguanide, DPP4 inhibitors, SGLT2 inhibitors)

Enrolling by invitation
  • Abdominal Obesity
  • Type 2 Diabetes
  • Biguanide, DPP4 inhibitors, SGLT2 inhibitors
  • San Luis Potosi, Mexico
    Metabolic Research Unit
Sep 1, 2021

Type 2 Diabetes Trial in Dundee (Sulfonylurea, DPP4 Inhibitor)

Completed
  • Type 2 Diabetes
  • Dundee, United Kingdom
    Ninewells Hospital and Medical School
Mar 3, 2021

Type 2 Diabetic Saudi Arabia Treated With Empagliflozin to

Completed
Has Results
  • Diabetes Mellitus, Type 2
  • Abha, Saudi Arabia
  • +20 more
Feb 9, 2022

Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in

Completed
  • Diabetes Mellitus, Type 2
  • Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
  • Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Gentofte, Denmark
  • +12 more
Jan 18, 2022

DPP4 Inhibitor and Coronary Atherosclerosis in Patients

Completed
  • Diabetes Mellitus
  • Bucheon, Korea, Republic of
    Bucheon St. Mary's Hospital
Apr 26, 2021

Type 2 Diabetes, Incretinomimetics, Pancreas Trial in Brussels (Incretinomimetics, DPP-4 inhibitors)

Recruiting
  • Type 2 Diabetes
  • +2 more
  • Brussels, Belgium
    Gastroenterology Department Erasme Hospital
Mar 1, 2021

Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA

Not yet recruiting
  • Cerebral Infarction
  • +2 more
  • Dipeptidyl peptidase-4 inhibitor
  • (no location specified)
Apr 5, 2023

Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,

Recruiting
  • Glucose Metabolism Disorders
  • +3 more
  • Empagliflozin 10 MG
  • Insulin+Metformin+DPP4 inhibitor (DPP4I)
  • Karachi, Pakistan
    SINA Shireen Jinnah colony
Nov 28, 2023

Platelet Aggregation During Acute Myocardial Infarction Trial in São Paulo (sitagliptin OR saxagliptin, )

Completed
  • Platelet Aggregation During Acute Myocardial Infarction
  • sitagliptin OR saxagliptin
  • placebo
  • São Paulo, SP, Brazil
    Heart Institute(InCor)-Acute Coronary Care Unit
Aug 26, 2020

Dapagliflozin Versus DPP-4 Inhibitors

Completed
  • Type 2 Diabetes
  • Padova, Italy
    University Hospital of Padova
Mar 9, 2020

Sodium-glucose Cotransporter 2 Inhibitors Among Type 2 Diabetes

Completed
  • Diabetes Mellitus, Type 2
  • +3 more
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • +2 more
  • Montreal, Quebec, Canada
    Lady Davis Institute for Medical Research, Jewish General Hospit
Aug 17, 2020

Sodium-glucose Cotransporter 2 Inhibitors and Risk of

Completed
  • Type2 Diabetes
  • +5 more
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Montreal, Quebec, Canada
    Lady Davis Institute for Medical Research, Jewish General Hospit
Oct 1, 2020

Short Bowel Syndrome Trial in Skawina (Dipeptidyl peptidase-4 inhibitor)

Terminated
  • Short Bowel Syndrome
  • Dipeptidyl peptidase-4 inhibitor
  • Skawina, Poland
    Stanley Dudrick's Memorial Hospital
Apr 13, 2020

NAFLD Trial (sitagliptin and metformin, Sitagliptin, Metformin)

Completed
  • NAFLD
  • sitagliptin and metformin
  • +2 more
  • (no location specified)
Jul 28, 2022

Diabetes, Type 2 Trial in Worldwide (Insulin icodec, Insulin glargine U100)

Completed
Has Results
  • Diabetes Mellitus, Type 2
  • Insulin icodec
  • Insulin glargine U100
  • Walnut Creek, California
  • +37 more
Jan 6, 2022